Women with aortic stenosis had a lower rate of all cause mortality and fewer ischaemic cardiovascular events then men, in a randomised controlled trial. However, rate of disease progression was similar for both genders. Data were used from the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study, a randomised, double-blind, placebo-controlled trial which assessed the effect of combined treatment with simvastatin and ezetimibe on the progression of mild to moderate aortic stenosis and cardiovascular morbidity and mortality.